NCT03231293 (FABULOUS) is a clinical trial in Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd.

Who is sponsoring NCT03231293?

NCT03231293 is sponsored by Boryung Pharmaceutical Co., Ltd.

What condition does NCT03231293 study?

NCT03231293 studies Hypertension, Ischemic Stroke, Transient Ischemic Attack.

Is NCT03231293 still recruiting?

NCT03231293 is currently completed. Last updated 4 November 2019.

Last reviewed 2019-11-04 · How we verify

NCT03231293: FABULOUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fimasartan Blood Pressure Lowering After Acute Stroke

Completed Last updated 4 November 2019

What this trial tests

trial in Hypertension in 1,035 participants. Completed in 5 April 2019.

Timeline

28 July 2016

Primary endpoint
2 November 2018

5 April 2019

Quick facts

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,035
Start date	28 July 2016
Primary completion	2 November 2018
Estimated completion	5 April 2019
Sites	27 locations across South Korea

Conditions studied

Hypertension — all drugs for Hypertension →
Ischemic Stroke — all drugs for Ischemic Stroke →
Transient Ischemic Attack — all drugs for Transient Ischemic Attack →

Sponsor

Boryung Pharmaceutical Co., Ltd — full company profile →

Who can join

19 and older, any sex, with Hypertension or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study.
Hong KS, Kwon SU, Park JH, Cha JK, et al · · 2021 · cited 1× · PMID 34184441 · DOI 10.3988/jcn.2021.17.3.344

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Boryung Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07421414 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421401 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421388 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421375 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07373613 — A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03231293 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boryung Pharmaceutical Co., Ltd
Last refreshed: 4 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03231293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing